Every S-3 that Allarity Therapeutics, Inc. (ALLR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow ALLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLR filings page.
Allarity Therapeutics, Inc. filed Amendment No. 1 to its registration statement (File No. 333-293420) on April 24, 2026 as an exhibits-only amendment to furnish an updated auditor consent. The Amendment updates Exhibit 23.1 and includes the facing page, Item 16, signature page, exhibit index, and filed exhibits; the prospectus is unchanged.
Allarity Therapeutics is registering 255,103 shares of common stock for resale by a single selling stockholder. These shares were issued on December 23, 2025 as “Additional Shares” in a private placement at $0.98 per share, which previously generated approximately $250,000 in gross proceeds for the company.
The resale registration is purely for the stockholder’s benefit; Allarity will not receive any proceeds when these shares are sold. As context, 16,080,980 shares of common stock were outstanding as of February 11, 2026, and the Nasdaq closing price that day was $0.90 per share.
In earlier tranches of the private placement, Allarity sold 760,916 shares and 801,584 pre-funded warrants for roughly $2.5 million in gross proceeds and may sell up to $6.0 million of additional stock over time under a separate equity line agreement. The company remains a clinical-stage oncology business focused on stenoparib and operates as an emerging growth and smaller reporting company, highlighting ongoing capital needs and potential future dilution.
Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.